Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - fortacin
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp7595bd80b37f1612e8b528f48e44afff
identifier: http://ema.europa.eu/identifier
/EU/1/13/881/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Fortacin 150 mg/ml + 50 mg/ml cutaneous spray, solution
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-7595bd80b37f1612e8b528f48e44afff
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/13/881/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - fortacin
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Fortacin is a combination of two medicines: lidocaine and prilocaine. These belong to a group of medicines called local anaesthetics.
Fortacin is indicated for the treatment of premature ejaculation occurring in adult men (aged 18 years and over) from first sexual intercourse. This is when you always, or nearly always, have ejaculated within one minute of sexual intercourse and this causes you negative emotional effects. Fortacin works by decreasing the sensitivity of the head of the penis to increase time before ejaculation.
Do not use Fortacin
Warnings and precautions Talk to your doctor or pharmacist before using Fortacin
Premature ejaculation may be due to a condition requiring medical supervision. If this product used as directed does not provide relief, consult a doctor.
Use with condoms
Avoid accidental contact
Contact with other mucous membranes
Possible transfer to partner, e.g. to vagina or the anus
Children and adolescents This medicine should not be used in children or adolescents under 18 years of age.
Other medicines and Fortacin Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. It is particularly important that you talk to a doctor before using Fortacin if you are taking any of the following medicines which may interact with Fortacin:
The risk of methaemoglobinaemia can also be increased by the use of certain dyes (aniline dyes), or the pesticide naphthalene, so let your doctor know if you work with any dyes or chemical pesticides.
Pregnancy, breast-feeding and fertility Fortacin is not approved for use by women.
Ask your doctor or pharmacist for advice before taking any medicine.
Pregnancy Fortacin should not be used whilst your partner is pregnant unless you use an effective male condom, as listed above in section 2 Use with condoms , to prevent exposure of the unborn child.
Breast-feeding This medicine may be used while your partner is breast-feeding.
Fertility Fortacin may reduce the possibility of pregnancy. Therefore, patients hoping to achieve conception should either avoid using Fortacin, or, if this medicine is essential to achieve penetration, should wash the penis as thoroughly as possible five minutes after Fortacin has been applied, but prior to intercourse.
Driving and using machines Fortacin has no or negligible influence on the ability to drive and use machines when used at the recommended doses.
Always use this medicine exactly as described in this leaflet. Check with your doctor or pharmacist if you are not sure.
The recommended dose of Fortacin is 3 sprays (3 sprays = 1 dose) on the head of the penis at least 5 minutes before sexual intercourse. A maximum of 3 doses can be used within 24 hours with at least 4 hours between doses.
The maximum recommended dose (3 doses within 24 hours) should not be exceeded.
Instructions for use
If you use more Fortacin than you should If you do apply too much, wipe it off.
Symptoms of using too much Fortacin are listed below. Contact your doctor or pharmacist if you experience any of these. They are very unlikely to happen if it is used as instructed:
In serious cases of overdose, symptoms may include fits, low blood pressure, slowed breathing, stopped breathing and altered heart beat. These effects may be life-threatening.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The following side effects have been reported with Fortacin in male patients:
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
The following side effects have been reported with Fortacin in sexual partners:
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Reporting of side effects If you or your sexual partner get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the spray container label and the carton after EXP . The expiry date refers to the last day of that month.
Store below 25 C. Do not freeze. You must throw away the container 12 weeks after you first use it. The metal container is pressurised. Do not puncture, break or burn it even when apparently empty. A residual volume of fluid that is not usable will remain in the container after all doses have been administered.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
What Fortacin contains
What Fortacin looks like and contents of the pack Fortacin is a colourless to light yellow cutaneous spray, solution in an aluminium spray container with metering valve. The metering valve s components are the stainless steel, POM, TPE, polypropylene, chlorobutyl rubber and HDPE.
Each pack contains 1 spray container with 6.5 ml or 5 ml of solution.
Marketing Authorisation Holder
Recordati Ireland Limited Raheens East Ringaskiddy Co. Cork P43 KDIreland
Manufacturer Genetic S.p.A. Via Canfora, 84084 Fisciano (SA) Italy
Recordati Industria Chimica e Farmaceutica S.p.A. Via Matteo Civitali 1 20148 Milano Italy
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Belgi /Belgique/Belgien Recordati Ireland Ltd. T l/Tel: + 353 21 4379Lietuva Recordati Ireland Ltd. Tel: + 353 21 4379
Recordati Ireland Ltd. Te .: + 353 21 4379Luxembourg/Luxemburg Recordati Ireland Ltd. T l/Tel: + 353 21 4379 esk republika Herbacos Recordati s.r.o. Tel: + 420 466 741 Magyarorsz g Recordati Ireland Ltd. Tel.: + 353 21 4379Danmark Recordati Ireland Ltd. Tlf: + 353 21 4379Malta Recordati Ireland Ltd. Tel: + 353 21 4379Deutschland Recordati Pharma GmbH Tel: + 49 (0) 731 7047 0
Nederland Recordati Ireland Ltd. Tel: + 353 21 4379Eesti Recordati Ireland Ltd. Tel: + 353 21 4379Norge Recordati Ireland Ltd. Tlf: + 353 21 4379
Recordati Hellas Pharmaceuticals A.E. : + 30 210-6773 sterreich Recordati Ireland Ltd. Tel: + 353 21 4379Espa a Casen Recordati, S.L. Tel: + 34 91 659 15 Polska RECORDATI POLSKA sp. z o.o. Tel.: + 48 22 206 84 France Laboratoires BOUCHARA-RECORDATI T l: + 33 1 45 19 10 Portugal Jaba Recordati, S.A. Tel: + 351 21 432 95 Hrvatska Recordati Ireland Ltd. Tel: + 353 21 4379Rom nia Recordati Rom nia S.R.L. Tel: + 40 21 667 17 Ireland Recordati Ireland Ltd. Tel: + 353 21 4379Slovenija Recordati Ireland Ltd. Tel: + 353 21 4379 sland Recordati Ireland Ltd. S mi: + 353 21 4379Slovensk republika Herbacos Recordati s.r.o. Tel: + 420 466 741 Italia Recordati Industria Chimica e Farmaceutica S.p.A. Tel: + 39 02 487Suomi/Finland Recordati Ireland Ltd. Puh/Tel: + 353 21 4379
Recordati Ireland Ltd. : + 353 21 4379Sverige Recordati Ireland Ltd. Tel: + 353 21 4379Latvija Recordati Ireland Ltd. Tel: + 353 21 4379United Kingdom (Northern Ireland) Recordati Ireland Ltd. Tel: + 353 21 4379This leaflet was last revised in {MM/YYYY}
Other sources of information Detailed and updated information on this medicine is available by scanning the QR code below and the outer carton with a smartphone. The same information is also available on the following URL: www.fortacin.eu QR code www.fortacin.eu
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-7595bd80b37f1612e8b528f48e44afff
Resource Composition:
Generated Narrative: Composition composition-en-7595bd80b37f1612e8b528f48e44afff
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/13/881/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - fortacin
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp7595bd80b37f1612e8b528f48e44afff
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp7595bd80b37f1612e8b528f48e44afff
identifier:
http://ema.europa.eu/identifier
/EU/1/13/881/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Fortacin 150 mg/ml + 50 mg/ml cutaneous spray, solution
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en